drugset

drugset / Trial / NCT02483260

Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever

NCT02483260 ↗

Suspended 30 enrolled U.S. Army Medical Research and Development Command

NaSingle-groupOpen-labelTreatment

Summary

Is ribavirin a therapeutic option for patients with a probable or suspected case of viral hemorrhagic fever?

Timeline

Start: 2016-06-16
Primary completion: 2027-10
Completion: 2028-12

Outcome

Outcome not reported

Stopped: “Product expired, new lots are not available.”

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ribavirin	Small molecule	8 mg/kg	Intravenous

Indications